Acessibilidade / Reportar erro
Erratum • Arch. Endocrinol. Metab. 66 (4) • 2022 • https://doi.org/10.20945/2359-3997000000520   copy
This erratum corrects:

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment

DOI: 10.20945/2359-3997000000451

Arch Endocrinol Metab. 2022;66(2):269-71

Where you read:

Mohammad Esmatinia 1

https://orcid.org/0000-0001-8582-5658

Should read:

Mahdi Mottaghi 1

https://orcid.org/0000-0001-8582-5658

Publication Dates

  • Publication in this collection
    30 Sept 2022
  • Date of issue
    2022
Creative Common - by 4.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Sociedade Brasileira de Endocrinologia e Metabologia Rua Botucatu, 572 - Conjuntos 81/83, 04023-061 São Paulo SP Brasil, Tel: (55 11) 5575-0311 - São Paulo - SP - Brazil
E-mail: aem.editorial.office@endocrino.org.br
Acompanhe os números deste periódico no seu leitor de RSS